8X23
 
 | | The Crystal Structure of MAPK13 from Biortus. | | Descriptor: | 1,2-ETHANEDIOL, GLYCEROL, Mitogen-activated protein kinase 13 | | Authors: | Wang, F, Cheng, W, Yuan, Z, Lin, D, Pan, W. | | Deposit date: | 2023-11-09 | | Release date: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (1.5 Å) | | Cite: | The Crystal Structure of MAPK13 from Biortus.
To Be Published
|
|
4YNO
 | |
5EKO
 | | Crystal structure of MAPK13 complex with inhibitor | | Descriptor: | 3-(4-methyl-1H-imidazol-1-yl)-N-[4-(pyridin-4-yloxy)phenyl]benzamide, Mitogen-activated protein kinase 13 | | Authors: | Brett, T.J, Miller, C.A, Yurtsever, Z. | | Deposit date: | 2015-11-03 | | Release date: | 2016-07-06 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.
Biochim.Biophys.Acta, 1860, 2016
|
|
3COI
 | | Crystal structure of p38delta kinase | | Descriptor: | Mitogen-activated protein kinase 13 | | Authors: | Atwell, S, Burley, S.K, Houle, A, Ramos, A, Sauder, J.M, New York SGX Research Center for Structural Genomics (NYSGXRC) | | Deposit date: | 2008-03-28 | | Release date: | 2008-04-15 | | Last modified: | 2023-08-30 | | Method: | X-RAY DIFFRACTION (2.09 Å) | | Cite: | Crystal structure of p38delta kinase.
To be Published
|
|
4EYJ
 | | MAPK13 Complex with inhibitor | | Descriptor: | 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-yloxy)phenyl]urea, Mitogen-activated protein kinase 13 | | Authors: | Miller, C.A, Brett, T.J. | | Deposit date: | 2012-05-01 | | Release date: | 2012-12-19 | | Last modified: | 2023-09-13 | | Method: | X-RAY DIFFRACTION (2.102 Å) | | Cite: | IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
J.Clin.Invest., 122, 2012
|
|
4EYM
 | | MAPK13 complex with inhibitor | | Descriptor: | 2-(morpholin-4-yl)-N-[4-(pyridin-4-yloxy)phenyl]pyridine-4-carboxamide, Mitogen-activated protein kinase 13 | | Authors: | Miller, C.A, Brett, T.J. | | Deposit date: | 2012-05-01 | | Release date: | 2012-12-19 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.353 Å) | | Cite: | IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
J.Clin.Invest., 122, 2012
|
|
4MYG
 | | MAPK13, active form | | Descriptor: | Mitogen-activated protein kinase 13 | | Authors: | Yurtsever, Z, Brett, T.J, Scheaffer, S.M. | | Deposit date: | 2013-09-27 | | Release date: | 2015-03-25 | | Last modified: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (2.594 Å) | | Cite: | The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation.
Acta Crystallogr.,Sect.D, 71, 2015
|
|
5EKN
 | | Crystal structure of MAPK13 complex with inhibitor | | Descriptor: | 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-ylsulfanyl)phenyl]urea, Mitogen-activated protein kinase 13 | | Authors: | Brett, T.J, Miller, C.A, Yurtsever, Z. | | Deposit date: | 2015-11-03 | | Release date: | 2016-07-06 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.594 Å) | | Cite: | First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.
Biochim.Biophys.Acta, 1860, 2016
|
|
